Cambridge, MA | August 2026 A novel drug sequestrant-based therapeutic candidate reverses methamphetamine-induced hyperthermia and hypermetabolism and abates multiorgan toxicity in rats - ScienceDirect In a preclinical study funded by the National Institute on Drug Abuse, CS-1103 protected against methamphetamine overdose, for which there are currently no medications. This pioneering work was conducted by Dr. Joe Cotten, MD, PhD and Dr. Elie Adam, PhD at Mass General Brigham

Cambridge, MA | August 2026 Clear Scientific, a clinical-stage biopharmaceutical company, was awarded a $5.2M award from the NIH’s National Institute on Drug Abuse to continue the development of CS-1103 through Phase 2 clinical trials for the reversal of methamphetamine intoxication. Illicit stimulant use, especially methamphetamine, is a major public health crisis for which there are no FDA-approved therapeutics. Clear Scientific has raised an additional $2.6M in an open SA

Boston, MA | June 2026 https://www.youtube.com/live/kic6w7fgBQI?si=9ONxIWdNwEok4Nl1&t=7552 Clear Scientific’s CEO, Shekar Shetty, and General Counsel, Winston Henderson, joined the June 9th Boston’s GBH radio show, The Curiosity Desk hosted by Edgar B. Herwick III.  GBH’s newest show is live weekday afternoons from 1 to 2 p.m. EST and focuses on conversations, insights and profundities about the world we live in. Tune in to listen to the Clear Scientific team discuss the dev